TNFR2: The new Treg switch?

TNFR2: The new Treg switch?

Three recent publications identified the TNF/TNR2 pathway as a new target to reduce graft-versus-host-disease through regulatory T cells activation or to potentially switch on a strong anti-leukemic effect through regulatory T cells blockade in allogeneic hematopoietic stem cell transplantation. Thi...

Bibliografske podrobnosti
Main Authors:	Cohen, JL, Wood, KJ
Format:	Journal article
Jezik:	English
Izdano:	Taylor and Francis 2017

Podobne knjige/članki

TNFR2: The new Treg switch?
od: José L. Cohen, et al.
Izdano: (2018-01-01)

TNFR1 and TNFR2 Expression and Induction on Human Treg Cells from Type 1 Diabetic Subjects
od: Melanie Heinrich, et al.
Izdano: (2015-03-01)

TNFR2 blockade promotes antitumoral immune response in PDAC by targeting activated Treg and reducing T cell exhaustion
od: Eliane Piaggio, et al.
Izdano: (2024-11-01)

A TNFR2-Agonist Facilitates High Purity Expansion of Human Low Purity Treg Cells.
od: Xuehui He, et al.
Izdano: (2016-01-01)

Fn14 and TNFR2 as regulators of cytotoxic TNFR1 signaling
od: Daniela Siegmund, et al.
Izdano: (2023-11-01)

TNFR1 and TNFR2 in the Control of the Life and Death Balance of Macrophages
od: Harald Wajant, et al.
Izdano: (2019-05-01)

Co-modulation of TNFR1 and TNFR2 in an animal model of multiple sclerosis
od: Timon Fiedler, et al.
Izdano: (2023-04-01)

Lower Frequency of CD62Lhigh and Higher Frequency of TNFR2+ Tregs Are Associated with Inflammatory Conditions in Type 1 Diabetic Patients
od: Monika Ryba, et al.
Izdano: (2011-01-01)

The TNFR-I and TNFR-II loci in systemic lupus erythematosus
od: Eskdale, J, et al.
Izdano: (1997)

The Roles of TNFR2 Signaling in Cancer Cells and the Tumor Microenvironment and the Potency of TNFR2 Targeted Therapy
od: Hiroyuki Takahashi, et al.
Izdano: (2022-06-01)

Leukocyte TNFR1 and TNFR2 Expression Contributes to the Peripheral Immune Response in Cases with Ischemic Stroke
od: Rikke B. Hansen, et al.
Izdano: (2021-04-01)

Preclinical and clinical aspects of TNF-α and its receptors TNFR1 and TNFR2 in breast cancer
od: Isela Martínez-Reza, et al.
Izdano: (2017-12-01)

Distinct Role of TNFR1 and TNFR2 in Protective Immunity Against Orientia tsutsugamushi Infection in Mice
od: Yuejin Liang, et al.
Izdano: (2022-04-01)

Dichotomous outcomes of TNFR1 and TNFR2 signaling in NK cell-mediated immune responses during inflammation
od: Timothy R. McCulloch, et al.
Izdano: (2024-11-01)

TNFR2: Role in Cancer Immunology and Immunotherapy
od: Yang Y, et al.
Izdano: (2021-04-01)

Differential expression of TNFR1 (CD120a) and TNFR2 (CD120b) on subpopulations of human monocytes
od: Hijdra Daniëlle, et al.
Izdano: (2012-10-01)

TNFR1 and ANKYLOSING SPONDYLITIS
od: Karaderi, T, et al.
Izdano: (2010)

Genetic Knock-out of TNFR1 and TNFR2 in a JAK2-V617F Polycythemia Vera Mouse Model
od: Peter Müller, et al.
Izdano: (2022-05-01)

The TNF-α/TNFR2 Pathway: Targeting a Brake to Release the Anti-tumor Immune Response
od: Audrey Moatti, et al.
Izdano: (2021-10-01)

TNFR-associated factor-2 (TRAF-2) in Alzheimer's disease.
od: Culpan, D, et al.
Izdano: (2009)

The association between TNF-receptors (TNFR1 and TNFR2) and mortality as well as kidney function decline in patients with chronic kidney disease
od: Per Wändell, et al.
Izdano: (2024-11-01)

Serum DNase1, sTNFR1 and sTNFR2 as Risk Factors for Lupus Nephritis in Systemic Lupus Erythematosus Patients
od: Ida Ayu Ratih Wulansari Manuaba, et al.
Izdano: (2024-06-01)

Sequential treatment with a TNFR2 agonist and a TNFR1 antagonist improves outcomes in a humanized mouse model for MS
od: Valentina Pegoretti, et al.
Izdano: (2023-05-01)

TACE/ADAM17 substrates associate with ACS (Ep-CAM, HB-EGF) and follow-up MACE (TNFR1 and TNFR2)
od: Melody Chemaly, et al.
Izdano: (2022-12-01)

The rs11684747 and rs55790676 SNPs of ADAM17 influence tuberculosis susceptibility and plasma levels of TNF, TNFR1, and TNFR2
od: José Alberto Choreño-Parra, et al.
Izdano: (2024-05-01)

Editorial: TNFR Superfamily Oligomerization and Signaling
od: Olivier Micheau, et al.
Izdano: (2021-04-01)

TNFR signalling and its clinical implications
od: Tseng, W, et al.
Izdano: (2016)

The Immunosuppressive Effect of TNFR2 Expression in the Colorectal Cancer Microenvironment
od: Nurul Hakimah Mohd Salim, et al.
Izdano: (2023-01-01)

Therapeutic potential of TNFR2 agonists: a mechanistic perspective
od: Yibo Chen, et al.
Izdano: (2023-08-01)

Targeting TNFR2: A Novel Breakthrough in the Treatment of Cancer
od: Muchun Li, et al.
Izdano: (2022-04-01)

Targeting TNFR2 in Cancer: All Roads Lead to Rome
od: Jingchao Bai, et al.
Izdano: (2022-02-01)

TNFR-associated factor-2 (TRAF-2) expression in Alzheimer's disease
od: Culpan, D, et al.
Izdano: (2004)

TNFR2 blockade of regulatory T cells unleashes an antitumor immune response after hematopoietic stem-cell transplantation
od: Moatti, A, et al.
Izdano: (2022)

841 LBL-019, a novel TNFR2 agonist antibody, shows potent anti-tumor efficacy through preferentially activating CD8+ T cells and alleviating the suppressive effect of Treg cells
od: Tingting Li, et al.
Izdano: (2023-11-01)

Editorial: Targeting TNF/TNFR signaling pathways
od: Liqiang Pan, et al.
Izdano: (2023-01-01)

TNFR1 Absence Is Not Crucial for Different Types of Cell Reaction to TNF: A Study of the TNFR1-Knockout Cell Model
od: Alina A. Alshevskaya, et al.
Izdano: (2024-04-01)

Identification of novel inhibitors for TNFα, TNFR1 and TNFα-TNFR1 complex using pharmacophore-based approaches
od: Madhu Sudhana Saddala, et al.
Izdano: (2019-07-01)

Targeting sTNF/TNFR1 Signaling as a New Therapeutic Strategy
od: Roman Fischer, et al.
Izdano: (2015-03-01)

Understanding the role of TNFR2 signaling in the tumor microenvironment of breast cancer
od: Ali Mussa, et al.
Izdano: (2024-11-01)

Targeting TNFR2 for cancer immunotherapy: recent advances and future directions
od: Linxue Li, et al.
Izdano: (2024-09-01)